Evidence map›Paper›PMID 22587896›Full record

ArticleClinical chemistry2012

Temperature-tolerant COLD-PCR reduces temperature stringency and enables robust mutation enrichment.

E Castellanos-Rizaldos, Pingfang Liu, Coren A Milbury, Minakshi Guha, Angela Brisci, Laura Cremonesi, Maurizio Ferrari, Harvey Mamon, G Mike Makrigiorgos

Abstract read
In one paragraph

Article in Clinical chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Detection ofInternational journal of molecular sciences · 2025
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

E Castellanos-RizaldosDivision of DNA Repair and Genome Stability, Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Pingfang Liu
Coren A Milbury
Minakshi Guha
Angela Brisci
Laura Cremonesi
Maurizio Ferrari
Harvey Mamon
G Mike Makrigiorgos

Funding

GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR33CA111994 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2007 to 2008
$656k
GENOME AMPLIFICATION TOLERANT TO SAMPLE DEGRADATIONR21CA111994 · NCI · DANA-FARBER CANCER INSTITUTE · PI MAKRIGIORGOS, G. MIKE · 2005 to 2006
$290k
High-throughput technology that enables sequencing depth for colorectal CAR21CA151164 · NCI · DANA-FARBER CANCER INST · PI MAKRIGIORGOS, G. MIKE · 2011 to 2012
$241k
NCI NIH HHS CA-111994NCI NIH HHS CA-151164NCI NIH HHS R21 CA111994NCI NIH HHS R21 CA151164NCI NIH HHS R33 CA111994
6 · The paper itself

Abstract

backgroundLow-level mutations in clinical tumor samples often reside below mutation detection limits, thus leading to false negatives that may impact clinical diagnosis and patient management. COLD-PCR (coamplification at lower denaturation temperature PCR) is a technology that magnifies unknown mutations during PCR, thus enabling downstream mutation detection. However, a practical difficulty in applying COLD-PCR has been the requirement for strict control of the denaturation temperature for a given sequence, to within ±0.3 °C. This requirement precludes simultaneous mutation enrichment in sequences of substantially different melting temperature (T(m)) and limits the technique to a single sequence at a time. We present a temperature-tolerant (TT) approach (TT-COLD-PCR) that reduces this obstacle.

methodsWe describe thermocycling programs featuring a gradual increase of the denaturation temperature during COLD-PCR. This approach enabled enrichment of mutations when the cycling achieves the appropriate critical denaturation temperature of each DNA amplicon that is being amplified. Validation was provided for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) and TP53 (tumor protein p53) exons 6-9 by use of dilutions of mutated DNA, clinical cancer samples, and plasma-circulating DNA.

resultsA single thermocycling program with a denaturation-temperature window of 2.5-3.0 °C enriches mutations in all DNA amplicons simultaneously, despite their different T(m)s. Mutation enrichments of 6-9-fold were obtained with TT-full-COLD-PCR. Higher mutation enrichments were obtained for the other 2 forms of COLD-PCR, fast-COLD-PCR, and ice-COLD-PCR.

conclusionsLow-level mutations in diverse amplicons with different T(m)s can be mutation enriched via TT-COLD-PCR provided that their T(m)s fall within the denaturation-temperature window applied during amplification. This approach enables simultaneous enrichment of mutations in several amplicons and increases significantly the versatility of COLD-PCR.

Indexed as

Brain NeoplasmsCell Line, TumorColorectal NeoplasmsDNADNA Mutational AnalysisGlioblastomaHumansLung NeoplasmsMaleMutationNucleic Acid DenaturationPolymerase Chain ReactionProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsTemperatureDNAKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)ras ProteinsTumor Suppressor Protein p53

Identifiers

PMID22587896
PMCPMC3418919

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.